CeriBell, Inc.
Ceribell, Inc. (CBLL)
Overview
Ceribell, Inc. is a Nasdaq-listed medical technology company based in Sunnyvale, California that has developed a point-of-care electroencephalography (EEG) platform for acute care settings. The company went public in October 2024 at $17.00 per share and has since grown rapidly: fiscal 2025 revenue reached $89.06 million, up 36.1% from $65.44 million in 2024, and trailing-twelve-month revenue stood at $101.96 million (up 31.7%) as of the most recent data available, with the company guiding full-year 2026 revenue to $114-117 million (28-31% growth). Gross margins hit a record 87% in the first quarter of 2026, reflecting a favorable disposables-driven business model, though Ceribell remains unprofitable, posting a net loss of $53.41 million in 2025 and roughly $66 million on a trailing-twelve-month basis as it continues to invest heavily in commercial expansion. Ceribell employs 327 people and is led by co-founder and CEO Dr. Xingjuan Chao.
What They Do & How They Make Money
Ceribell's core product, the Ceribell System, is a rapid, point-of-care EEG platform designed to detect seizures and other acute neurological events at the bedside — in emergency departments, intensive care units, and other acute care settings — without requiring a trained neurologist or technician to place traditional EEG electrodes, a process that can otherwise take hours. The system combines a disposable, easy-to-apply headband, a pocket-sized wireless recorder, and Clarity, an AI-powered seizure-detection algorithm that gives clinicians rapid, actionable guidance. Ceribell also operates a remote EEG portal enabling off-site neurologist review. The company's revenue model follows a classic medical-device "razor-and-blade" structure: it places recorder hardware with hospitals and then generates high-margin, recurring revenue from disposable headbands used with each patient, which explains its high and improving gross margins. A significant recent catalyst is the company's CMS New Technology Add-on Payment (NTAP) reimbursement approval for its Delirium Monitor System, expanding the reimbursed, billable use cases for its platform beyond seizure detection alone.
Competitors
Ceribell competes in the broader neurological monitoring and diagnostics market against:
- Traditional EEG system manufacturers such as Natus Medical, whose conventional EEG equipment requires specialized technician placement and is not designed for rapid point-of-care use.
- General patient-monitoring companies that could expand into point-of-care neuro-monitoring as the category grows.
- Emerging point-of-care neuro-diagnostic startups targeting similar acute-care seizure and delirium detection use cases.
- The clinical status quo — many hospitals still rely on slower, standard EEG workflows or clinical judgment alone rather than any point-of-care device, representing Ceribell's largest practical "competitor" in terms of market penetration.
Competitive Position
Ceribell holds meaningfully stronger competitive advantages than most companies in this batch: it has FDA-cleared, patent-protected proprietary technology (the Clarity AI algorithm) addressing a genuine clinical gap — rapid seizure and delirium detection at the bedside, where traditional EEG is too slow. Its disposable-headband, recurring-revenue business model produces high (87%) and improving gross margins, and its new CMS reimbursement approval for the Delirium Monitor System both expands its addressable clinical use cases and locks in favorable economics that would be difficult for a new entrant to replicate quickly, since reimbursement approval processes are lengthy. Once a hospital trains its emergency department and ICU staff on the Ceribell workflow and integrates it into clinical protocols, switching to an alternative (or reverting to traditional EEG) carries real workflow and retraining costs. The company still faces real risk from continued net losses as it invests in commercial expansion, and its moat depends on maintaining its clinical and reimbursement lead as larger medical device companies could eventually target the same point-of-care EEG niche. Ceribell's outlook depends on converting its raised fiscal 2026 revenue guidance into a path toward profitability while defending its first-mover position in point-of-care EEG monitoring.